IP Library Granted Patent US 12,600,699
Granted Patent B2
US 12,600,699 · App. 18/073,689 · Granted Apr 14, 2026

Thiosemicarbazates and uses thereof

Inventors: Yousef Al-Abed (Manhasset, NY); Ahmad Altiti (Piscataway, NJ)
Assignee: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
C07D209/48C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,699
App. No.
18/073,689
Granted
Apr 14, 2026
Kind
B2
Abstract

Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics. Methods for preparing and using ureases, carbazides, semicarbazides, beta-peptides, azapeptides, and other peptidomimetics and azapeptide conjugates, and uses of ureases, carbazides, semicarbazides, beta-peptides, azapeptides in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are also described.

Claims (39)

1 . A compound of the Formula (I):

wherein

A is H;

Y is a NR 1 ;

X is NR 5 ;

D is H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1 is H; or

R 1 and R 5 are joined together by —(CH 2 —CH 2 —CH 2 )—; and

R 5 is substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkoxyalkylene, optionally protected alkyl amine, or a side chain radical of a natural or unnatural amino acid, which is substituted one or more times by one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, —COOR, —COR, methoxy, ethoxy, propoxy, C 1 -C 6 haloalkyl, and a protecting group, wherein R is an alkyl, or unsubstituted, and wherein, when said amino acid is a natural amino acid, the natural amino acid is selected from the group consisting of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine, arginine, asparagine, and glutamine.

2 . The compound of claim 1 , wherein R 1 and R 5 are joined together by —(CH 2 —CH 2 —CH 2 )—.

3 . The compound of claim 1 , wherein R 5 is a side chain radical of a natural amino acid, which is unsubstituted.

4 . The compound of claim 3 , wherein the natural amino acid is selected from the group consisting of aspartic acid, alanine, phenylalanine, histidine, glutamic acid, tryptophan, methionine, tyrosine, arginine, asparagine, and glutamine.

5 . The compound of claim 4 , wherein the natural amino acid is phenylalanine.

6 . The compound according to claim 1 , wherein the natural amino acid is selected from the group consisting of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine, arginine, asparagine, and glutamine, which is substituted one or more times by one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, —COOR, —COR, methoxy, ethoxy, propoxy, C 1 -C 6 haloalkyl, and a protecting group, wherein R is alkyl.

7 . The compound of claim 1 , wherein the side chain radical is a residue from an unnatural amino acid.

8 . The compound of claim 7 , wherein the residue from the unnatural amino acid is unsubstituted.

9 . The compound of claim 7 , wherein R 5 is a side chain radical of an unnatural amino acid, and the unnatural amino acid is selected from the group consisting of a β-amino acid, an aliphatic amino acid, β-cyclohexyl-L-alanine, 6-aminohexanoic acid, L-α,β-diaminopropionic acid, L-propargylglycinel, L-α,β-diaminopropionic acid, α-aminoisobutyric acid, β-(2-pyridyl)-L-alanine, β-(3-pyridyl)-L-alanine, β-cyclopropyl-L-alanine, β-t-butyl-L-alanine, (2,4-dinitrophenyl))-L-α,β-diaminopropionic acid, (allyloxycarbonyl)-L-α,β-diaminopropionic acid, D-α,β-diaminopropionic acid, L-α,β-diaminopropionic acid, (N-γ-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-L-α,γ-diaminobutyric acid, (N-γ-4-methyltrityl)-L-α,γ-diaminobutyric acid, L-α,γ-diaminobutyric acid, 4-fluoro-L-phenylglycine, 5,5,5-trifluoro-DL-leucine, epsilon-aminohexanoic-OH, L-α-t-butylglycine, L-2-amino-3-(dimethylamino)propionic acid, L-2-aminocaproic acid, L-allylglycine, lysine azide, (N-8-4-methyltrityl)-L-ornithine, Arg(Me)(Pbf)-OH, dimethyl-L-arginine (symmetrical and unsymmetrical), L-2-amino-3-guanidinopropionic acid, L-citrulline, ε-acetyl-L-lysine, Lys(ivDde)-OH, Lys(Me)2-OH·HCl, Lys(Me3)-OHchloride, α-methyl-DL-glutamic acid, γ-carboxy-L-glutamic acid γ,γ-di-t-butyl ester, (N-γ-ethyl)-L-glutamine, 2,6-diaminopimelic acid, Glu(OAll)-OH, L-cysteic acid, α-methyl-DL-methionine, DL-buthionine, L-cysteic acid, L-selenomethionine, S-[2-(4-pyridyl)ethyl]-L-cysteine, S-[2-(4-pyridyl)ethyl]-L-cysteine, S-diphenylmethyl-L-cysteine, S-trityl-L-homocysteine, S-trityl-L-penicillamine, (Se-p-methoxybenzyl)-L-selenocysteine, β-hydroxyphenylalanine, 2-cyano-L-phenylalanine, L-thyroxine, O-methyl-L-tyrosine, β-methyl-DL-phenylalanine, 2-cyano-L-phenylalanine, L-thyroxine, O-methyl-L-tyrosine, β-methyl-DL-phenylalanine, 2-cyano-L-phenylalanine, 3,4-dichloro-L-phenylalanine, 3,4-difluoro-L-phenylalanine, 3,4-dihydroxy-L-phenylalanine, 3,4-dihydroxy-phenylalanine, 3-amino-L-tyrosine, 3-chloro-L-tyrosine, 3-fluoro-DL-tyrosine, 3-nitro-L-tyrosine, 4-amino-L-phenylalanine, 4-aminomethyl-L-phenylalanine, 4-(phosphonomethyl)-phenylalanine, 4-benzoyl-D-phenylalanine, 4-bis(2-chloroethyl) amino-L-phenylalanine, 4-cyano-L-phenylalanine, 4-fluoro-L-phenylalanine, 4-iodo-L-phenylalanine, DL-m-tyrosine, 2,6-dimethyl-tyrosine, L-homophenylalanine, O-methyl-L-tyrosine, Phe(4-guanidino)-OH, O-benzyl-L-phosphotyrosine, (2S,3R)-3-phenylpyrrolidine-2-carboxylic acid, (2S,4S)-4-phenyl-pyrrolidine-2-carboxylic acid, (2S,3aS,7aS)-Octahydro-1H-indole-2-carboxylic acid, (2S,3R)-3-phenylpyrrolidine-2-carboxylic acid, (2S,4R)-(−)-4-t-butoxypyrrolidine-2-carboxylic acid, trans-4-fluoro-L-proline, (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid, 4-amino-3-hydroxybutanoic acid, L-a-methylserine, (2S,3S)-2-amino-3-methoxybutanoic acid, Thr(β-D-GlcNAc(Ac) 3)-OH, O-benzyl-L-phosphoserine, O-benzyl-D-phosphothreonine, O-benzyl-L-phosphothreonine, 4-methyl-DL-tryptophan, 6-fluoro-DL-tryptophan, 6-methyl-DL-tryptophan, DL-7-azatryptophan, (R)-7-Azatryptophan, 5-benzyloxy-DL-tryptophan, 5-bromo-DL-tryptophan, 5-chloro-DL-tryptophan, 5-fluoro-DL-tryptophan, 5-hydroxy-L-tryptophan, 5-methoxy-L-tryptophan, 6-chloro-L-tryptophan, 6-methyl-DL-tryptophan, 7-methyl-DL-tryptophan, DL-7-azatryptophan, 5-azido-pentanoic acid, 2-amino-N-(3-azidopropyl)-3-mercaptopropionamide, 2-amino-N-(3-azidopropyl)-3-mercaptopropionamide, Azidohomoalanine, L-propargylglycine·DCHA, azidolysine, p-azidophenylalanine, Azidohomoalanine, D-propargylglycine, L-propargylglycine, azidolysine, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, 2-(7′-octenyl) alanine, 2-(4′-pentenyl) alanine, 2-(4′-pentenyl) glycine, 2-(7′-octenyl) alanine, [5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid], L-glutamic acid-γ-[2-(1-sulfonyl-5-naphthyl)-aminoethylamide], N-8-(5-carboxyfluorescein)-L-lysine, N-ε-(5/6-carboxyfluorescein)-L-lysine, N-ε-(4,4-dimethylazobenzene-4′carbonyl)-L-lysine, N-8-2,4-dinitrophenyl-L-lysine, N-ε-[(7-methoxycoumarin-4-yl)-acetyl-L-lysine, glycosylated amino acids (e.g., Ser(β-D-GlcNAc (Ac) 3)-OH, Thr(β-D-GlcNAc(Ac)3)-OH), 3-azabicyclo[3.1.0]hexane-2-carboxylic acid, 4-amino-(1-carboxymethyl) piperidine, 4-phenylpiperidine-4-carboxylic acid, Nα-methyl-N-im-trityl-L-histidine, Nα-methyl-O-benzyl-L-serine dicyclohexylammonium salt, N-alpha-methyl-N-omega-(4-methoxy-2,3,6-trimethylbenzenesulfonyl)-L-arginine, N-alpha-methyl-L-leucine, Nalpha-methyl-L-norvaline, N-alpha-methyl-L-phenylalanine, N-alpha-methyl-N-im-trityl-L-histidine, N-alpha-methyl-O-t-butyl-L-serine, N-alpha-methylglycine, 21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid, {2-[2-(amino)-ethoxy]-ethoxy}acetic acid, 6-amino-4-oxahexanoic acid, 5-amino-3-oxapentamoic acid, NH-(PEG)10-CH 2 CH 2 COOH, NH-(PEG) 12-CH 2 CH 2 COOH, 9-Amino-4; 7-dioxanonanoic acid, 9-amino-4; 7-dioxanonanoic acid, 12-amino-4,7,10-trioxadodecanoic acid, 15-amino-4,7,10,13-tetraoxapentadecacanoic acid, 18-amino-4,7,10,13,16-pentaoxaoctadecanoic acid, 21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid, NH-(PEG) 8-CH 2 CH 2 COOH, 11-amino-3,6,9-trioxaundecanoic acid, N-(Fmoc-8-amino-3,6-dioxa-octyl) succinamic acid, —N-ε-acetyl-L-lysine, L-citrulline, Arg(Me)(Pbf)-OH, N-ω,ω-dimethyl-L-arginine, Lys(Me) 2-OH chloride, N-8,8-t-methyl-L-lysine, Lys(Me3)-OH chloride, O-benzyl-L-phosphoserine, O-benzyl-D-phosphothreonine and O-benzyl-L-phosphothreonine, and O-benzyl-L-phosphotyrosine, which are unsubstituted or substituted by one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, —COOR, —COR, methoxy, ethoxy, propoxy, C 1 -C 6 haloalkyl, and a protecting group, wherein R is alkyl.

10 . The compound of claim 9 , wherein the unnatural amino acid is a β-amino acid or an aliphatic amino acid, which is unsubstituted or substituted one or more times by one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, —COOR, —COR, methoxy, ethoxy, propoxy, C 1 -C 6 haloalkyl, and a protecting group, wherein R is alkyl.

11 . The compound of claim 10 , wherein the β-amino acid is selected from the group consisting of L-β-homotyrosine, β-alanine, L-β-homoasparagine, L-β-homoalanine, L-β-homophenylalanine, homotryptophan, homoserine, homocysteine, L-β-homoproline, L-β-homoolysine, L-β-homorarginine, and L-β-proline.

12 . The compound of claim 10 , wherein the aliphatic amino acid is selected from the group consisting of 6-aminohexanoic acid, 2-amino-3-methoxybutanoic acid, 1-aminocyclopentane-1-carboxylic acid, 2-(aminooxy) acetic acid, and 6-aminohaxanoic acid, 2-[2-(amino)-ethoxy]-ethoxy}acetic acid.

13 . The compound of claim 1 , wherein D is H, alkyl, or aryl, wherein said alkyl or aryl are unsubstituted or substituted one or more times by one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, —COOR, —COR, methoxy, ethoxy, propoxy, and C 1 -C 6 haloalkyl, wherein R is alkyl.

14 . A compound of the Formula (I):

wherein

A is H;

Y is a NR 1 ;

X is NR 5 ;

D is H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 1 is H; and

R 5 is a side chain radical of a natural amino acid selected from the group consisting of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine, arginine, asparagine, and glutamine, which is unsubstituted or substituted one or more times by one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, —COOR, —COR, methoxy, ethoxy, propoxy, C 1 -C 6 haloalkyl, and a protecting group, wherein R is alkyl.

15 . The compound of claim 14 , wherein the natural amino acid is unsubstituted.

16 . The compound of claim 15 , wherein the natural amino acid is selected from the group consisting of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, methionine, tyrosine, isoleucine, arginine, asparagine, and glutamine.

17 . A compound of the Formula (I):

wherein

A is H;

Y is a NR 1 ;

X is NR 5 ;

D is a substituted or unsubstituted alkyl,

R 1 is H; and

R 5 is a side chain radical of a natural amino acid selected from the group consisting of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine, arginine, asparagine, and glutamine, which is unsubstituted or substituted one or more times by one or more substituents selected from the group consisting of halo, C1-C6 alkyl, —COOR, —COR, methoxy, ethoxy, propoxy, C 1 -C 6 haloalkyl, and a protecting group, wherein R is an alkyl.

Continuity (4)
Continuation 17831504 · Jun 3, 2022
Division 16869749 · May 8, 2020
Provisional Application 62845694 · May 9, 2019
Related Publication 20230111252A1 · Apr 13, 2023
References Cited (56)
US 4282169A · Rothgery · 1981 [cited by examiner]
US 4713381A · Ao · 1987 [cited by examiner]
US 5602231A · Cotton et al. · 1997 [cited by applicant]
US 7531533B2 · Shoda · 2009 [cited by applicant]
US 8563565B2 · Norimine et al. · 2013 [cited by applicant]
US 9186371B2 · Taniguchi et al. · 2015 [cited by applicant]
US 10919882B2 · Al-Abed et al. · 2021 [cited by applicant]
US 11414405B2 · Al-Abed et al. · 2022 [cited by applicant]
US 11440881B2 · Al-Abed · 2022 [cited by examiner]
US 11471507B2 · Al-Abed et al. · 2022 [cited by applicant]
US 11471508B2 · Al-Abed et al. · 2022 [cited by applicant]
US 11524048B2 · Al-Abed · 2022 [cited by applicant]
US 20060281686A1 · Lopez Areiza et al. · 2006 [cited by applicant]
US 20110086836A1 · Soeberdt et al. · 2011 [cited by applicant]
US 20180344808A1 · Tracey et al. · 2018 [cited by applicant]
US 20190055283A1 · Ekici et al. · 2019 [cited by applicant]
US 20200354404A1 · Al-Abed · 2020 [cited by applicant]
US 20200354418A1 · Al-Abed · 2020 [cited by applicant]
US 20210188837A1 · Shikanai et al. · 2021 [cited by applicant]
US 20220306577A1 · Al-Abed et al. · 2022 [cited by applicant]
US 20220372022A1 · Al-Abed et al. · 2022 [cited by applicant]
CN 101932568A · 2010 [cited by applicant]
EP 1847533A1 · 2007 [cited by applicant]
GB 826300 · 1959 [cited by applicant]
JP 2001075232A · 2001 [cited by applicant]
WO WO0140515A1 · 2001 [cited by applicant]
WO WO2009096609A1 · 2009 [cited by applicant]
WO WO2016094899A2 · 2016 [cited by applicant]
WO WO2019131582A1 · 2019 [cited by applicant]
Nathalie Ollivier et al., “Silver Catalyzed azaGly Ligation. Application to the Synthesis of Azapeptides and of Lipid-Peptide Conjugates”, Bioconjugate Chem, vol. 20, pp. 1397-1403, 2009. [cited by applicant]
Ramesh Chingle et al., “Azapeptide Synthesis Methods for Expanding Side-Chain Diversity for Biomedical Applications”, Accounts of Chemical Research, vol. 50, pp. 1541-1556, 2017. [cited by applicant]
Branka Zorc et al., “Benzotriazole as a Synthetic Auxiliary”, Croatica Chemica Acta, 85(4), pp. 959-601, 2012. [cited by applicant]
Ye Che et al., “Impact of Cis-Proline Analogs Peptide Conformation”, Biopolymers, vol. 81, pp. 392-406, 2006. [cited by applicant]
International Search Report issued on Sep. 2, 2020, from corresponding International Application No. PCT/US20/31998. [cited by applicant]
Written Opinion of the International Searching Authority issued on Sep. 2, 2020, from corresponding International Application No. PCT/US20/31998. [cited by applicant]
PubChem CID-136595533 “(2,5-Dioxopyrrol-1-yl) N-(2,5-dihydroxypyrrol-1-yl)-N-(1,3-dioxoisoindol-2-yl)carbamate” Created on Jan. 4, 2019. [cited by applicant]
PubChem CID-132255576 “(2S)-2-(Imidazole-1-carbonylamino)pentanedioic acid” Created on Jan. 29, 2018. [cited by applicant]
International Search Report issued on Jul. 31, 2020, from corresponding International Application No. PCT/US20/32025. [cited by applicant]
Written Opinion of the International Searching Authority issued on Jul. 31, 2020, from corresponding International Application No. PCT/US20/32025. [cited by applicant]
Yang et al. “MD-2 is required for disulfide HMGB1-dependent TLR4 signaling” The Journal of Experimental Medicine; Published on Jan. 5, 2015; vol. 212; p. 5-14. [cited by applicant]
Sun et al. “Folic acid derived-P5779 mimetics regulate DAMP-mediated inflammation through disruption of HMGB1:TLR4:MD-2 axes” PLOS ONE; Published on Feb. 15, 2018; vol. 13; p. 1-14. [cited by applicant]
International Search Report issued on Sep. 10, 2020, from corresponding International Application No. PCT/US20/31992. [cited by applicant]
Written Opinion of the International Searching Authority issued on Sep. 10, 2020, from corresponding International Application No. PCT/US20/31992. [cited by applicant]
PubChem CID-519335 “Methanethioic S-acid” Created on Mar. 27, 2005. [cited by applicant]
Heffeter et al. “Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development” Antioxidants & Redox Signaling; vol. 30, No. 8, 2019. [cited by applicant]
International Search Report issued on Sep. 16, 2020, from corresponding International Application No. PCT/US20/31988. [cited by applicant]
Written Opinion of the International Searching Authority issued on Sep. 16, 2020, from corresponding International Application No. PCT/US20/31988. [cited by applicant]
PubChem CID-67548889 “Methyl (2S)-1-(imidazole-1-carbonyl)pyrrolidine-2-carboxylate” Created on Nov. 30, 2012. [cited by applicant]
PubChem CID-1089188 “(2s)-1-(1-Imidazolylcarbonyl)pyrrolidine-2-carboxylic acid benzyl ester” Created on Oct. 26, 2006. [cited by applicant]
Riemschneider, R. JACS 1955, 844-847. [cited by applicant]
Cécile Abbas et al., “Original and efficient synthesis of 2:1-[α/aza]-oligomer precursors”, Tetrahedron Letters, vol. 50, No. 28, pp. 4158-4160, Jul. 15, 2009. [cited by applicant]
Noam S. Freeman et al., “Microwave-Assisted Solid-Phase Aza-peptide Synthesis: Aza Scan of a PKB/Akr Inhibitor Using Aza-arginine and Aza-proline Precursors”, The Journal of Organic Chemistry, vol. 76, No. 9, pp. 3078-3… [cited by applicant]
Mariappan Anbazhagan et al., “Conversion of Carbonimidodithioates into Unsymmetrical Di- and tri-substituted Ureas including Urea Dipeptides”, Tetrahedron Letters, vol. 39, No. 21, pp. 3609-3612, 1998. [cited by applicant]
European Search Report issued on Dec. 9, 2022, from corresponding European Application No. EP 20 80 2822. [cited by applicant]
Harper, H.A. et al. “Review of physiological chemistry” [cited by applicant]
Carine B. Bourguet et al., “Solution-phase submonomer diversification of the aza-dipeptide building blocks and their application in aza-peptide and aza-DKP synthesis”, Journal of Peptide Science, vol. 16, No. 6, Jun. 1,… [cited by applicant]